Abstract 609P
Background
Pembrolizumab, a checkpoint inhibitor, has revolutionized the treatment of advanced melanoma by harnessing the immune system to target cancer cells. However, its use is associated with immune-related adverse events, including vitiligo and thyroid function abnormalities. This study aims to investigate the association between thyroid function abnormalities and vitiligo induced by pembrolizumab, specifically focusing on the prognosis in patients with advanced melanoma.
Methods
A retrospective survey of medical records and treatment outcomes of patients with locally advanced/metastatic melanoma receiving pembrolizumab was conducted. The study reported data on the incidence of vitiligo, thyroid function abnormalities, and their impact on prognosis. Data was collected from multiple oncology centers across Iraq. Kaplan-Meier survival curves and Cox regression were used for statistical analysis.
Results
One hundred cases with advanced melanoma were included in this study. The mean age of the samples was 55.8 ± 15.5 years old. Male to female ratio was 0.79. The Incidence of vitiligo was reported to be 27%, mainly in the survived-group (35.2%, P-value = 0.046). It took an average of 12 weeks for the development of vitiligo. The incidence of thyroid dysfunction was found to be 22%. The development of vitiligo significantly improved survival in patients with advanced melanoma (log-rank test = 0.043). On the other hand, the occurrence of thyroid dysfunction as an immune-side effect to treatment did not have an effect on the overall survival of the cohort.
Conclusions
The findings of this study suggest that there is an association between the incidence of vitiligo induced by pembrolizumab and overall survival in patients with advanced melanoma. However, no such relationship was found in regard to the development of thyroid dysfunction.
Clinical trial identification
Editorial acknowledgement
Dr. Ahmed Z. Al-Samaraee, Medical oncologist, Oncology teaching hospital, Baghdad Dr Maha S. Sahib, Clinical Pharmacist, Baghdad Dr Ayad R Alasadi, Medical oncologist, Al-Amal Hospital, Baghdad.
Legal entity responsible for the study
Oncology Teaching Hospital, Medical City Complex, Baghdad.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
613P - Differences in the interactions with pharmaceutical companies between medical oncologists and infectious diseases physicians
Presenter: Hui Ling Yeoh
Session: Poster Display
Resources:
Abstract
614P - The role of PD-L1 expression in prognosis of osteosarcoma patients: A systematic review and meta-analysis
Presenter: Alexander Purnomo
Session: Poster Display
Resources:
Abstract
615P - Pulmonary resectable metastases of osteosarcoma with apatinib and chemotherapy (PROACH): An open-label, single-arm phase II clinical trial
Presenter: Qiyuan Bao
Session: Poster Display
Resources:
Abstract
616P - Incidence of cardiotoxicity after high cumulative dose of anthracyclines in adult patients with advanced soft tissue sarcomas: A systematic review and meta-analysis
Presenter: Paula Franco
Session: Poster Display
Resources:
Abstract
617P - The risk of acute myeloid leukaemia in patients with Ewing's sarcoma and trend analysis: A SEER-based study 2000-2020
Presenter: Mohamed Abdalla
Session: Poster Display
Resources:
Abstract
618P - Adult renal Ewing’s sarcoma/primitive neuroectodermal tumor: A 20-year retrospective review of molecular histopathological profiles, and clinical outcomes
Presenter: Josh Thomas Georgy
Session: Poster Display
Resources:
Abstract
619P - Single-cell and bulk RNA-seq analyses decode the renal microenvironment induced by polystyrene microplastics in mice receiving high-fat diet
Presenter: Wangrui Liu
Session: Poster Display
Resources:
Abstract
620P - A unique circulating microRNA pairs signature serves as a superior tool for early diagnosis of pan-cancer
Presenter: Dongyu Li
Session: Poster Display
Resources:
Abstract
621P - Effective identification of primary liver cancer from cirrhosis or chronic hepatitis virus infection using eight methylated plasma DNA markers: Marker discovery, phase I pilot, and phase II clinical validation
Presenter: Tian Yang
Session: Poster Display
Resources:
Abstract
622P - A prognostic and immune infiltration analysis of CCL26 in pan-cancer
Presenter: Mengyue Li
Session: Poster Display
Resources:
Abstract